Publication:
Retos y avances del cáncer de pulmón de células no pequeñas metastásico EGFR mutado

Simple item page
dc.contributor.authorCastro-Mollo, M
dc.contributor.authorRuiz, R
dc.contributor.authorRoque, K
dc.contributor.authorMas, L
dc.date.accessioned2025-02-05T17:29:27Z
dc.date.available2025-02-05T17:29:27Z
dc.date.issued2024
dc.description.abstractIntroduction: Tyrosine kinase inhibitors have dramatically changed the clinical outcomes for patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutations. However, there are still challenges in the management of patients with this mutation in a metastatic setting, such as intrinsic and acquired resistance to tyrosine kinase inhibitors. We will discuss the latest advances and new strategies in first-line treatment, osimertinib resistance, and exon 20 mutation treatment. © 2024 Universidad Ricardo Palma, Facultad de Medicina Humana. All rights reserved.
dc.formatapplication/pdf
dc.identifier.doi10.25176/RFMH.v24i2.6441
dc.identifier.journalRevista de la Facultad de Medicina Humana
dc.identifier.urihttps://hdl.handle.net/20.500.14703/351
dc.language.isoeng
dc.publisherUniversidad Ricardo Palma, Instituto de Investigaciones en Ciencias Biomedicas, Facultad de Medicina Humana
dc.publisher.countryPE
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectEpidermal growth factor receptor
dc.subjectNon-small cell Lung cancer
dc.subjectTyrosine kinase inhibitors
dc.subject.ocdehttps://purl.org/pe-repo/ocde/ford#3.02.21
dc.titleRetos y avances del cáncer de pulmón de células no pequeñas metastásico EGFR mutado
dc.typeinfo:eu-repo/semantics/review
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication

Files

Collections

Artículos originales